Tyrzepatyd: interakcje

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (etykieta leku Chlorochina, Ostrzeżenia)

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (etykieta leku Cyprofloksacyna, Interakcje z innymi lekami)

Diabetic ketoacidosis should be treated with insulin [see Warnings and Precautions (5.1) and Warnings and Precautions (5.2) ] . (etykieta leku Dapagliflozyna + metformina, Przeciwwskazania)

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (etykieta leku Flukonazol, Interakcje z innymi lekami)

These conditions should be treated with insulin. (etykieta leku Glibenklamid, Przeciwwskazania)

Diabetic ketoacidosis should be treated with insulin. (etykieta leku Glipizyd + metformina, Przeciwwskazania)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)

To avoid medication errors between LEVEMIR and other insulins, instruct patients to always check the insulin label before each injection. (etykieta leku Insulina detemir, Ostrzeżenia i środki ostrożności)

To avoid medication errors between LYUMJEV and other insulins, instruct patients to always check the insulin label before each injection. (etykieta leku Insulina lispro, Ostrzeżenia i środki ostrożności)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etykieta leku Tyrzepatyd, Ostrzeżenie w ramce)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etykieta leku Tyrzepatyd, Ostrzeżenie w ramce)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etykieta leku Tyrzepatyd, Ostrzeżenie w ramce)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etykieta leku Tyrzepatyd, Ostrzeżenie w ramce)

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (etykieta leku Protamina, Ostrzeżenie w ramce)

Diabetic ketoacidosis should be treated with insulin. (etykieta leku Saksagliptyna + metformina, Przeciwwskazania)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etykieta leku Tyrzepatyd, Ostrzeżenie w ramce)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etykieta leku Tyrzepatyd, Ostrzeżenie w ramce)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (etykieta leku Abirateron, Ostrzeżenia i środki ostrożności)

Diabetes and Hypoglycemia β-blockers may potentiate insulin-induced hypoglycemia and mask some of its manifestations such as tachycardia; however, dizziness and sweating are usually not significantly affected. (etykieta leku Acebutolol, Ostrzeżenia)

Consideration should be taken in patients being treated with antidiabetic agents. (etykieta leku Acetazolamid, Interakcje z innymi lekami)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (etykieta leku Acytretyna, Interakcje z innymi lekami)

When such drugs are withdrawn from patients receiving acarbose tablets in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia. (etykieta leku Akarboza, Interakcje z innymi lekami)

Alkohol może powodować niskie stężenie cukru we krwi przy stosowaniu insuliny lub pochodnych sulfonylomocznika, a intensywne picie przy stosowaniu metforminy zwiększa ryzyko kwasicy mleczanowej. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (etykieta leku Alogliptyna, Ostrzeżenia i środki ostrożności)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin and metformin HCl tablets. (etykieta leku Alogliptyna + metformina, Ostrzeżenia i środki ostrożności)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (etykieta leku Amlodypina + benazepryl, Interakcje z innymi lekami)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etykieta leku Atazanawir, Ostrzeżenia i środki ostrożności)

At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (etykieta leku Atenolol + chlortalidon, Ostrzeżenia)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etykieta leku Beksaroten, Ostrzeżenia i środki ostrożności)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (etykieta leku Benazepryl, Interakcje z innymi lekami)

Antidiabetic agents: Dosage adjustment of antidiabetic drug may be required. (etykieta leku Benazepryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Unlike nonselective beta-blockers, betaxolol does not prolong insulin-induced hypoglycemia. (etykieta leku Betaksolol, Ostrzeżenia)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (etykieta leku Bexagliflozin, Ostrzeżenia i środki ostrożności)

Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (etykieta leku Bisoprolol, Ostrzeżenia)

Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (etykieta leku Bisoprolol + hydrochlorotiazyd, Ostrzeżenia)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (etykieta leku Brymonidyna + tymolol, Ostrzeżenia i środki ostrożności)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina, Interakcje z innymi lekami)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina + kodeina, Interakcje z innymi lekami)

Hypoglycemia Quinine stimulates release of insulin from the pancreas, and patients, especially pregnant women, may experience clinically significant hypoglycemia. (etykieta leku Chinina, Ostrzeżenia i środki ostrożności)

Antidiabetic Drugs (Oral Agents and Insulin) - dosage adjustment of the antidiabetic drug may be required. (etykieta leku Chlorotiazyd, Interakcje z innymi lekami)

Caution should be exercised when used with antidiabetic drugs. (etykieta leku Danazol, Interakcje z innymi lekami)

• Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with DAPAGLIFLOZIN TABLETS. (etykieta leku Dapagliflozyna, Ostrzeżenia i środki ostrożności)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (etykieta leku Darunawir, Ostrzeżenia i środki ostrożności)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etykieta leku Darunawir + kobicystat, Ostrzeżenia i środki ostrożności)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (etykieta leku Deksametazon, Ostrzeżenia i środki ostrożności)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (etykieta leku Dorzolamid + tymolol, Ostrzeżenia i środki ostrożności)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Dulaglutyd, Ostrzeżenia i środki ostrożności)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Eksenatyd, Ostrzeżenia i środki ostrożności)

The effects of increases in the concentration of the progestational component norgestimate are not fully known and can include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis. (etykieta leku Elwitegrawir + kobicystat + emtrycytabina + tenofowir, Interakcje z innymi lekami)

Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia. (etykieta leku Empagliflozyna, Ostrzeżenia i środki ostrożności)

Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia. (etykieta leku Empagliflozyna + metformina, Ostrzeżenia i środki ostrożności)

Anti-diabetic drugs (oral agents and insulin) Dosage adjustment of the anti-diabetic drug may be required. (etykieta leku Enalapryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (etykieta leku Fentermina, Ostrzeżenia i środki ostrożności)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (etykieta leku Fludrokortyzon, Interakcje z innymi lekami)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (etykieta leku Fluoksetyna, Ostrzeżenia i środki ostrożności)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etykieta leku Fosamprenawir, Ostrzeżenia i środki ostrożności)

Insulin requirements in diabetic patients may be increased, decreased, or unchanged. (etykieta leku Fozynopryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Tyrzepatyd, Ostrzeżenia i środki ostrożności)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Tyrzepatyd, Ostrzeżenia i środki ostrożności)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Tyrzepatyd, Ostrzeżenia i środki ostrożności)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etykieta leku Glukagon, Ostrzeżenia i środki ostrożności)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (etykieta leku Hydrochlorotiazyd, Interakcje z innymi lekami)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (etykieta leku Hydrokortyzon, Interakcje z innymi lekami)

Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin. (etykieta leku Hydroksykarbamid (hydroksymocznik), Ostrzeżenia i środki ostrożności)

Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairments and hypoglycemia unawareness ( 5. (etykieta leku Insulina aspart, Ostrzeżenia i środki ostrożności)

The risk of hypoglycemia after an injection is related to the duration of action of the insulin [see Clinical Pharmacology ( 12.2 )] and, in general, is highest when the glucose lowering effect of the insulin is maximal. (etykieta leku Insulina degludec, Ostrzeżenia i środki ostrożności)

For patients with type 2 diabetes, dosage adjustments of concomitant oral and antidiabetic products may be needed. (etykieta leku Insulina glargine, Ostrzeżenia i środki ostrożności)

For patients with type 2 diabetes mellitus, oral antidiabetic treatment dosage modifications may be needed. (etykieta leku Insulina ludzka krótko działająca, Ostrzeżenia i środki ostrożności)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (etykieta leku Irbesartan + hydrochlorotiazyd, Interakcje z innymi lekami)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (etykieta leku Itrakonazol, Interakcje z innymi lekami)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (etykieta leku Kanagliflozyna, Ostrzeżenia i środki ostrożności)

Antidiabetic drugs (oral agents and insulin) − Dosage adjustment of the antidiabetic drug may be required. (etykieta leku Kandesartan + hydrochlorotiazyd, Interakcje z innymi lekami)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (etykieta leku Kapecytabina, Interakcje z innymi lekami)

During the 8-week trial, serum insulin levels increased by 12 pmol/L in the VRAYLAR 1 mg to 2 mg per day group, 20 pmol/L in the VRAYLAR 2 mg to 4.5 mg per day group, and 8.5 pmol/L in the placebo group. (etykieta leku Kariprazyna, Ostrzeżenia i środki ostrożności)

Insulin and oral hypoglycemics action may be enhanced. (etykieta leku Karwedilol, Interakcje z innymi lekami)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (etykieta leku Ketokonazol, Interakcje z innymi lekami)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (etykieta leku Klarytromycyna, Ostrzeżenia i środki ostrożności)

…placebo) and when colesevelam hydrochloride was used in combination with pioglitazone (median increase 11% compared to placebo in combination with pioglitazone), sulfonylureas (median increase 18% compared to placebo in combination with sulfonylureas), and insulin (median increase 22% compared to placebo in combination with insulin) [see Adverse Reactions (6.1) ]. (etykieta leku Kolesewelam, Ostrzeżenia i środki ostrożności)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (etykieta leku Kwas acetylosalicylowy + dipirydamol, Interakcje z innymi lekami)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (etykieta leku Lanreotyd, Ostrzeżenia i środki ostrożności)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (etykieta leku Lewofloksacyna, Ostrzeżenia i środki ostrożności)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (etykieta leku Linagliptyna, Ostrzeżenia i środki ostrożności)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JENTADUETO XR. (etykieta leku Linagliptyna + metformina, Ostrzeżenia i środki ostrożności)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (etykieta leku Linezolid, Ostrzeżenia i środki ostrożności)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Liraglutyd, Ostrzeżenia i środki ostrożności)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (etykieta leku Lizynopryl, Interakcje z innymi lekami)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (etykieta leku Lizynopryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etykieta leku Lopinawir + rytonawir, Ostrzeżenia i środki ostrożności)

Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (etykieta leku Losartan + hydrochlorotiazyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues : Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (etykieta leku Metformina, Ostrzeżenia i środki ostrożności)

Insulin Clinical Impact Increased GI motility by metoclopramide may increase delivery of food to the intestines and increase blood glucose. (etykieta leku Metoklopramid, Interakcje z innymi lekami)

Insulin And Oral Antidiabetic Agents See Glucose Tolerance under PRECAUTIONS , General . (etykieta leku Metolazon, Interakcje z innymi lekami)

Antidiabetic drugs: Dosage adjustment may be required. (etykieta leku Metoprolol + hydrochlorotiazyd, Interakcje z innymi lekami)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etykieta leku Metyloprednizolon, Interakcje z innymi lekami)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Antidiabetic agents Carefully monitor blood glucose. (etykieta leku Moksyfloksacyna, Interakcje z innymi lekami)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (etykieta leku Nadolol, Ostrzeżenia)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (etykieta leku Naltrekson + bupropion, Ostrzeżenia i środki ostrożności)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Tyrzepatyd, Ostrzeżenia i środki ostrożności)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (etykieta leku Ofloksacyna, Ostrzeżenia)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etykieta leku Oktreotyd, Ostrzeżenia i środki ostrożności)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (etykieta leku Olmesartan + amlodypina + hydrochlorotiazyd, Interakcje z innymi lekami)

• Antidiabetic drugs: Dosage adjustment may be required. (etykieta leku Olmesartan + hydrochlorotiazyd, Interakcje z innymi lekami)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (etykieta leku Orlistat, Ostrzeżenia i środki ostrożności)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (etykieta leku Pindolol, Ostrzeżenia)

Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. (etykieta leku Pioglitazon, Ostrzeżenia i środki ostrożności)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Tyrzepatyd, Ostrzeżenia i środki ostrożności)

Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. (etykieta leku Pioglitazon + metformina, Ostrzeżenia i środki ostrożności)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etykieta leku Prednizolon, Interakcje z innymi lekami)

Antidiabetic agents: May increase blood glucose concentrations. (etykieta leku Prednizon, Interakcje z innymi lekami)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (etykieta leku Pregabalina, Ostrzeżenia i środki ostrożności)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Tyrzepatyd, Ostrzeżenia i środki ostrożności)

Decrease exposure Digitoxin Decrease exposure Fluoroquinolones Pefloxacin Administered with rifampin 900 mg daily Decrease exposure Moxifloxacin , Decrease exposure Oral Hypoglycemic Agents (e.g., sulfonylureas) Glyburide Decrease exposure Rifampin may worsen glucose control of glyburide. (etykieta leku Ryfampicyna, Interakcje z innymi lekami)

…Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines… (etykieta leku Ryfapentyna, Interakcje z innymi lekami)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etykieta leku Rytonawir, Ostrzeżenia i środki ostrożności)

• Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues: Consider a lower dosage of insulin or insulin secretagogue when used in combination wtih Saxagliptin tablets ( 5.3 ) (etykieta leku Saksagliptyna, Ostrzeżenia i środki ostrożności)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (etykieta leku Salsalat, Interakcje z innymi lekami)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : May increase the risk of hypoglycemia, including severe hypoglycemia. (etykieta leku Semaglutyd, Ostrzeżenia i środki ostrożności)

Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (etykieta leku Somatropina, Ostrzeżenia i środki ostrożności)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (etykieta leku Sotalol, Interakcje z innymi lekami)

Antidiabetic drugs (e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see Precautions ). (etykieta leku Spironolakton + hydrochlorotiazyd, Interakcje z innymi lekami)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (etykieta leku Sulfametoksazol + trimetoprim, Interakcje z innymi lekami)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etykieta leku Sunitynib, Ostrzeżenia i środki ostrożności)

Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (etykieta leku Sytagliptyna, Ostrzeżenia i środki ostrożności)

Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (etykieta leku Sytagliptyna + metformina, Ostrzeżenia i środki ostrożności)

Antidiabetic drugs: Dosage adjustment may be required ( 7.6 ) (etykieta leku Telmisartan + hydrochlorotiazyd, Interakcje z innymi lekami)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etykieta leku Temsyrolimus, Ostrzeżenia i środki ostrożności)

Insulin: In patients with diabetes, concomitant use with TLANDO may decrease blood glucose and insulin requirements ( 7.1) . (etykieta leku Testosteron, Interakcje z innymi lekami)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (etykieta leku Trandolapryl, Interakcje z innymi lekami)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (etykieta leku Tranylcypromina, Ostrzeżenia i środki ostrożności)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etykieta leku Triamcynolon, Interakcje z innymi lekami)

Infusion of glucose and insulin has also been used to treat hyperkalemia. (etykieta leku Triamteren, Ostrzeżenia i środki ostrożności)

Oral Hypoglycemic Drugs Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (etykieta leku Triamteren + hydrochlorotiazyd, Interakcje z innymi lekami)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (etykieta leku Tymolol, Ostrzeżenia i środki ostrożności)

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Antidiabetic Drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required. (etykieta leku Walsartan + hydrochlorotiazyd, Interakcje z innymi lekami)

• Effect of Smoking Cessation on Other Drugs: Pharmacokinetics or pharmacodynamics of certain drugs (e.g., theophylline, warfarin, insulin) may be altered, necessitating dose adjustment. (etykieta leku Wareniklina, Interakcje z innymi lekami)

Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with ZEPBOUND. (etykieta leku Tyrzepatyd, Interakcje z innymi lekami)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (etykieta leku Worykonazol, Interakcje z innymi lekami)

Antidiabetic drug requirements (i.e., insulin) may be altered. (etykieta leku Amfepramon (dietylopropion), Interakcje z innymi lekami)

Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. (etykieta leku Amiloryd, Ostrzeżenia)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (etykieta leku Bupropion, Ostrzeżenia i środki ostrożności)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (etykieta leku Fendimetrazyna, Interakcje z innymi lekami)

Hyperglycemia Hyperglycemia, resulting from the drug’s inhibitory effects on insulin release, has been reported. (etykieta leku Fenytoina, Ostrzeżenia i środki ostrożności)

Hyperglycemia Hyperglycemia, resulting from the inhibitory effect of phenytoin (the active metabolite of CEREBYX) on insulin release, has been reported. (etykieta leku Fosfenytoina, Ostrzeżenia i środki ostrożności)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (etykieta leku Klozapina, Ostrzeżenia i środki ostrożności)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (etykieta leku Lowastatyna, Interakcje z innymi lekami)

In an uncontrolled open-label trial of CAPLYTA for up to 1 year in adult patients with stable schizophrenia, the percentages of patients with shifts in fasting glucose and insulin values from normal to high were 8% and 12%, respectively. (etykieta leku Lumateperon, Ostrzeżenia i środki ostrożności)

Administer INCRELEX shortly before or after a meal or snack, because it has insulin-like hypoglycemic effects. (etykieta leku Mekasermina, Ostrzeżenia i środki ostrożności)

Insulin requirements in diabetes mellitus may be altered in association with the use of methamphetamine and the concomitant dietary regimen. (etykieta leku Metamfetamina, Interakcje z innymi lekami)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (etykieta leku Mikonazol, Interakcje z innymi lekami)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (etykieta leku Milrinon, Interakcje z innymi lekami)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (etykieta leku Moeksypryl, Interakcje z innymi lekami)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (etykieta leku Nifedypina, Środki ostrożności)

…been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine,… (etykieta leku Prazosyna, Interakcje z innymi lekami)

Administration of intravenous calcium, bicarbonate, and glucose with insulin, with hyperventilation have resulted in successful resuscitation in some of the reported cases. (etykieta leku Suksametonium, Ostrzeżenia i środki ostrożności)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (etykieta leku Sulfadiazyna, Interakcje z innymi lekami)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (etykieta leku Telmisartan + amlodypina, Interakcje z innymi lekami)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (etykieta leku Tolmetyna, Interakcje z innymi lekami)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (etykieta leku Zyprazydon, Ostrzeżenia i środki ostrożności)

Glyburide Clinical Impact: While oxaprozin does alter the pharmacokinetics of glyburide, coadministration of oxaprozin to type II non-insulin dependent diabetic patients did not affect the area under the glucose concentration curve nor the magnitude or duration of control. (etykieta leku Oksaprozyna, Interakcje z innymi lekami)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (etykieta leku Sulindak, Interakcje z innymi lekami)

Other interactions: Vardenafil hydrochloride tablets had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters). (etykieta leku Wardenafil, Interakcje z innymi lekami)